Clinical Effects of Chlormadinone Acetate (CMA) on Human Benign Prostatic Hypertrophy:Comparative Study with Paraprost by a Double Bhnd Trial

概要

論文の詳細を見る
The effects of chlormadinone acetate (CMA) on human benign prostatic hypertrophy was studied by a double blind trial using Paraprost (PPC) as a controL The administration of CMA was 50 mg per day for 16 weeks. The clinical results obtained were:<BR>1) Global judgement demonstrated that CMA group was significantly improved as compared with PPC group. Same results were also obtained by grading method examination.<BR>2) The radiologicamndings in urethrogram revealed that the degree of improvementin CMA group was significantly higher than that in PPC group. When examined by items, CMA group was significantly higher than PPC group in the degree of improvement both in estimation of prostatic volume by Thumann's method and elevation of bladder base.<BR>3) Seven patients of CMA group and one of PPC complained of a decline in potency, but all of them recovered from the symptom during the period of the administration of CMA or by the 8th week after the cease of the treatment.<BR>Judging from the above results, CMA is considered an useful drug for the conservative treatment in human benign prostatic hypertrophy.
一般社団法人日本臨床薬理学会の論文